Biocon's Baxter Global Research Center launched in Bangalore - The Times of India Manu Aiyappa,TNN | Feb 5, 2014, 09.33 PM IST BANGALORE: The rising incidence of chronic diseases like diabetes, cancer, cardiovascular and renal diseases pose an enormous challenge and disease burden for the various healthcare systems around the world. As a result, there was a compelling need to intensify research and development efforts for developing novel therapeutics and diagnostic capabilities that enable the government agencies to meet the challenges of affordability and access to treatment. Syngene International, a wholly owned subsidiary of Biocon, and Baxter International, a global pharmaceutical company, have collaborated to establish the Baxter Global Research Center (BGRC) aimed at making a contribution to this greater cause. Union health and family welfare minister Ghulam Nabi Azad inaugurated the new centre on Wednesday at Syngene in Biocon Park, off Hosur road. Speaking at the inaugural function, Kiran Mazumdar Shaw, chairperson, Biocon, said: "We share a common vision with Baxter, focused on developing pharmaceutical products that advance patient care worldwide, and this new research centre will be a significant step towards enabling that objective." The Syngene team, working closely with Baxter scientists, will engage in a wide range of R&D activities centered on product and analytical development and pre-clinical evaluation in parenteral nutrition and renal therapy, she added. Jean-Luc Butel, corporate vice-president and international president, Baxter, said: " Syngene facility dedicated to providing Baxter with technical and scientific capabilities will augment its internal resources and help save and sustain patients' lives worldwide" Commenting on the collaboration, Peter Bains, director, Syngene International Ltd, said: "A team of over 100 multidisciplinary Syngene scientists will be based at the centre. The collaboration will support Baxter in the research and development of medical products and devices to serve patients both in India and around the world''